Archiv anzeigen:

The 40th Annual San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research

A Curative Regimen for Peripheral T-Cell Lymphoma?

Michael E. Williams, MD, ScM reviewing Fanale MA et al. Blood 2018 Mar 5

The addition of brentuximab vedotin to front-line chemotherapy provided durable remissions in half of CD30-positive patients.

Hepcidin Agonists to Curb Iron Overload

David Green, MD, PhD reviewing Casu C et al. Blood 2018 Mar 9

A review of hepcidin mimetics and Tmprss6 inhibitors currently under development

Is There an Optimal Treatment for High-Risk Prostate Cancer?

Robert Dreicer, MD, MS, FACP, FASCO reviewing Kishan AU et al. JAMA 2018 Mar 6

External beam radiotherapy plus brachytherapy boost and androgen deprivation therapy outperformed other modalities in a retrospective study.

Do Antiphospholipid Antibodies Increase Risk for Recurrent Venous Thromboembolism?

David Green, MD, PhD reviewing Kearon C et al. Blood 2018 Feb 28

Patients with an elevated APA titer on two or more occasions had excess risk.

Breast Cancer Outcomes in BRCA-Mutation Carriers

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Feb, Fasching PA. Lancet Oncol 2018 Feb

Overall survival at 2, 5, and 10 years was similar between carriers and noncarriers.

Recognizing Endocrine Disorders: A Required Skill Set for Immuno-Oncology

William J. Gradishar, MD reviewing Barroso-Sousa R et al. JAMA Oncol 2018 Feb

Endocrine dysfunction was more common in patients receiving combination therapy versus monotherapy.

Inpatient Transfusion Trends in the U.S.

David Green, MD, PhD reviewing Goel R et al. JAMA 2018 Feb 27

Restrictive transfusion practices have decreased red cell and plasma transfusions during the past two decades.

Acalabrutinib Therapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Wang M et al. Lancet 2018 Feb, Kapoor P and Ansell SM. Lancet 2018 Feb

Most patients with relapsed or refractory disease responded; 67% remained progression-free at 12 months.

Familial Erythrocytosis Linked to EPO Gene Mutation

David Green, MD, PhD reviewing Zmajkovic J et al. N Engl J Med 2018 Mar 8

Gene sequencing revealed a single-base deletion in exon 2 of the EPO gene.

Seite von 66
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Daten nach 8 Jahren Follow-up in der WHI(Women’s Health Initiative)-Studie hatten eine gewisse Reduktion der Brustkrebstodesfälle durch eine Diät gezeigt, bei der weniger Fett, aber mehr Früchte, Gemüse und Ballaststoffe verzehrt wurden. Im jetzigen Bericht nach 16 Jahren Follow-up war diese Reduktion statistisch nicht mehr signifikant, es wurden aber eine leichte Verminderung der Zahl der prognostisch ungünstigeren Tumoren und weniger kardiovaskuläre Todesfälle berichtet.

Kommentar weiterlesen

Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.

Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.

Maintenance Immunotherapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Le Gouill S et al. N Engl J Med 2017 Sep 28

The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.

Adding Lorazepam to Haloperidol Might Help Alleviate Agitated Delirium in Advanced-Cancer Patients

Thomas L. Schwenk, MD reviewing Hui D et al. JAMA 2017 Sep 19, Pandharipande PP and Ely EW. JAMA 2017 Sep 19

Short-term reductions in agitation were helpful, but other components of delirium need further study.

Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.

Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes

Henry Mark Kuerer, MD, PhD, FACS reviewing Giuliano AE et al. JAMA 2017 Sep 12, Livingston EH and Li HC. JAMA 2017 Sep 12

Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.

Neoadjuvant Chemotherapy for Esophageal Adenocarcinoma

David H. Ilson, MD, PhD reviewing Alderson D et al. Lancet Oncol 2017 Sep

More intense preoperative chemotherapy fails to improve survival.

Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer

David H. Ilson, MD, PhD reviewing Overman MJ et al. Lancet Oncol 2017 Sep

The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.

Does Cutting Dietary Fat Affect Breast Cancer Outcomes?

Andrew M. Kaunitz, MD reviewing Chlebowski RT et al. J Clin Oncol 2017 Sep 1

Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.

Prothrombin Complex Concentrate for Bleeding from Direct Oral Anticoagulants

David Green, MD, PhD reviewing Majeed A et al. Blood 2017 Aug 23

Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.